Back to Search
Start Over
Dérivé de la bléomycine générant moins de ROS ? Moins de fibrose ? Une alternative dans le développement d’une thérapie anticancéreuse efficace mais moins toxique
- Source :
- Bulletin du Cancer. 97:527-534
- Publication Year :
- 2010
- Publisher :
- Elsevier BV, 2010.
-
Abstract
- Deglycobleomycin (DBLM), the aglycon of the glycopeptide antitumor drug bleomycin (BLM), was first used since 1980 during comparative studies between BLM and DBLM in order to elucidate the role of the sugar component in the mechanism of action of BLM. In fact, the deglycosylation of BLM reduce the toxicity of this molecule and fails to produce reactive oxygen species, responsible for pulmonary fibrosis, and for anti-neoplastic activity of BLM. This causes toxic DNA lesions and ultimately leads to cell death. The therapeutic use of BLM is limited by a dose-dependent lung toxicity that eventually leads to fibrosis. Testing BLM-derivative molecules and defining their molecular mechanisms involved in tumor cell death may help to design new therapeutic approach with limited toxicity profile while maintaining anti-tumoral properties. The present review was undertaken to determine the effect of carbohydrate moiety in the mechanism of BLM induced cytotoxicity behind a comparative studies between BLM and DBLM.
- Subjects :
- Drug
congenital, hereditary, and neonatal diseases and abnormalities
Cancer Research
urogenital system
media_common.quotation_subject
nutritional and metabolic diseases
Hematology
General Medicine
Bleomycin
medicine.disease
Molecular biology
chemistry.chemical_compound
Oncology
chemistry
Mechanism of action
Apoptosis
Fibrosis
Pulmonary fibrosis
Toxicity
medicine
Radiology, Nuclear Medicine and imaging
medicine.symptom
Cytotoxicity
media_common
Subjects
Details
- ISSN :
- 00074551
- Volume :
- 97
- Database :
- OpenAIRE
- Journal :
- Bulletin du Cancer
- Accession number :
- edsair.doi...........3a2331a28a58ecc58f42a1ab79f84e10